Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis
November 15, 2018
Patients with prior MI and elevated high-sensitivity C-reactive protein (hsCRP) see a dose-dependent reduction in heart-failure hospitalization while taking the anti-inflammatory drug canakinumab (Novartis), researchers reported Sunday at the American Heart Association (AHA) 2018 Scientific Sessions in Chicago, IL. The difference between canakinumab and placebo was only significant, however, among patients who achieved on-treatment hsCRP concentrations < 2 mg/L.
Visit Website